TrialBreast cancer research and treatment2021

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).

Lori J Goldstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.